Early Phase 1 Endometrial Cancer Trial, Recruiting NCT07278986 Sponsor: Abramson Cancer Center at Penn Medicine Condition: Endometrial Cancer
Back to Endometrial Cancer

Early Phase 1 Endometrial Cancer Trial, Recruiting

NCT07278986
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with endometrial cancer (cancer of the lining of the uterus)
  • People who are scheduled to have surgery for endometrial cancer
  • People who are able to understand what the study involves and agree to follow its rules and attend required appointments
  • People who are willing to stop taking folate or folic acid supplements at least 48 hours before receiving the study drug
  • People who have signed and dated a consent form agreeing to take part

Who may not be able to join:

  • People who are pregnant or who have a positive pregnancy test
  • People who have a medical condition that the study doctor believes could put them at risk during the trial (confirm with trial site)
  • People who have previously had a severe allergic reaction (anaphylaxis) to products containing indocyanine green (a dye used in medical imaging)
  • People who have a known allergy to any ingredient in CYTALUX (the study drug)
  • People who have psychological, family, social, or location-related circumstances that may make it difficult to follow the study schedule or attend follow-up visits

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: 215-615-6770

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Abramson Cancer Center at Penn Medicine
Registry
ClinicalTrials.gov
Start date
18 October 2025
Est. completion
1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Primary Endpoint

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov